Steuten Lotte M G, Ramsey Scott D
Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands.
Expert Rev Pharmacoecon Outcomes Res. 2014 Aug;14(4):491-8. doi: 10.1586/14737167.2014.914435. Epub 2014 Apr 28.
The rapidly increasing range and expense of new diagnostics, compels consideration of a different, more proactive approach to health economic evaluation of diagnostic technologies. Early cycle economic evaluation is a decision analytic approach to evaluate technologies in development so as to increase the return on investment as well as patient and societal impact. This paper describes examples of 'early cycle economic evaluations' as applied to diagnostic technologies and highlights challenges in its real-time application. It shows that especially in the field of diagnostics, with rapid technological developments and a changing regulatory climate, early cycle economic evaluation can have a guiding role to improve the efficiency of the diagnostics innovation process. In the next five years the attention will move beyond the methodological and analytic challenges of early cycle economic evaluation towards the challenge of effectively applying it to improve diagnostic research and development and patient value. Future work in this area should therefore be 'strong on principles and soft on metrics', that is, the metrics that resonate most clearly with the various decision makers in this field.
新型诊断方法的范围和成本迅速增加，这促使人们考虑采用一种不同的、更积极主动的方法来对诊断技术进行卫生经济评估。早期周期经济评估是一种决策分析方法，用于评估处于研发阶段的技术，以提高投资回报率以及对患者和社会的影响。本文介绍了应用于诊断技术的“早期周期经济评估”实例，并强调了其在实际应用中的挑战。研究表明，特别是在诊断领域，随着技术的快速发展和监管环境的变化，早期周期经济评估可以在提高诊断创新过程的效率方面发挥指导作用。在未来五年，关注重点将从早期周期经济评估的方法和分析挑战，转向有效应用该评估以改善诊断研发和患者价值的挑战。因此，该领域未来的工作应“原则强硬、指标灵活”，即采用与该领域各决策者最能产生共鸣的指标。
